2020
The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Marchi E, Ma H, Montanari F, Sawas A, Lue J, Deng C, Whitfield K, Klein S, Scotto L, Jain S, Lister J, Benanni N, Francescone M, Kim W, Zinzani P, O'Connor O. The Integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). Journal Of Clinical Oncology 2020, 38: 8049-8049. DOI: 10.1200/jco.2020.38.15_suppl.8049.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaGrade 3 hyponatremiaPhase 1b studyTreatment-related deathsGrade 3 thrombocytopeniaImmune checkpoint inhibitorsPreliminary clinical dataDose of drugPre-clinical modelsCancer-testis antigensCases of toxicityExperienced progressionFebrile neutropeniaRefractory PTCLStable diseaseComplete remissionPartial remissionPatient characteristicsClinical dataPharmacodynamic studiesTestis antigensPatientsTriple combinationResponse rate
2019
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
O’Connor O, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, Rada AM, Khan K, Jacob AT, Malanga M, Francescone MM, Nandakumar R, Soderquist CR, Park DC, Bhagat G, Cheng B, Risueño A, Menezes D, Shustov AR, Sokol L, Scotto L. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood 2019, 134: 1395-1405. PMID: 31471376, DOI: 10.1182/blood.2019001285.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaPhase 1 studyDay 1Day 8Response rateMulticenter phase 1 studyT-cell lymphoma patientsAdvanced lymphoid malignanciesTreatment-related deathsComplete response rateCoprimary end pointsGrade 3 thrombocytopeniaGrade 4 neutropeniaGrade 4 thrombocytopeniaOverall response rateT-cell lymphomaNon-T-cell lymphomasTumor mutational profileHistone deacetylase inhibitorsPTCL patientsPleural effusionLymphoma patientsLymphoid malignanciesEpigenetic modifiersPatients